KCT0001723招募中未知
A Trial of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Age 20 years or older
- •Histologically confirmed metastatic and/or advanced GIST with CD117(cluster of differentiation 117)(+), DOG-1(+), or mutation in KIT or PDGFRa gene(Platelet Derived Growth Factor Receptor)
- •Failed (progressed and/or intolerable) after prior treatments for GIST, including at least both imatinib and sunitinib .
- •Eastern Cooperative Oncology Group performance status of 0~2
- •Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-Common Toxicity Criteria for Adverse Effects version 3.0
- •At least one measurable lesion as defined by Response Evaluation Criteria In Solid Tumors version 1.0
- •Adequate bone marrow, hepatic, renal, and other organ functions
- •?Neutrophil > 1,500/mm3
- •?Platelet > 100,000/mm3
- •?Hemoglobin > 8.0 g/dL
- •?Total bilirubin < 1.5 x upper limit of normal (ULN)
- •?Aspartate aminotransferase /Alanine transferase< 2.5 x ULN (or < 5 x ULM in case of liver metastases)
- •?Creatinine < 1.5 x ULN
- •Life expectancy > 12 weeks
- •Washout period of previous TKIs(Tyrosine Kinase Inhibitor) or chemotherapy for more than 4 times the half life.
- •Provision of a signed written informed consent
排除标准
- •Exclusion Criteria:
- •Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control.
- •have the presence of cardiac disease,including a myocardial infarction within 6 months prior to study entry,Clinically significant cardiac disease (New York Heart Association, Class III or IV) or severe unstable angina pectoris, stroke or transient ischemic attack, Arrhythmia in need of treatment
- •Uncontrolled infection
- •Diabetes mellitus (insulin dependent or independent disease, requiring chronic medication) with signs of clinically significant peripheral vascular disease.
- •Acute and chronic liver disease and all chronic liver impairment.(Patients with stable and chronic viral hepatitis are eligible are acceptable)
- •Uncontrolled gastrointestinal toxicities with toxicity greater than NCI Common Toxicity Criteria for Adverse Effects grade 2
- •Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality.
- •The patient experienced any bleeding episode considered life-threatening, or any grade 3 or 4 bleeding event.
- •Major surgery = 28 days prior to starting study drug or who have not recovered from side effects of such therapy.
- •Known diagnosis of HIV infection .
- •History of another primary malignancy that is currently clinically significant or currently requires active intervention.
- •Patients with brain metastases as assessed by radiologic imaging
- •Alcohol or substance abuse disorder.
研究者
相似试验
招募中
1 期
An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel Amendment 1CancerACTRN12614000365662Kinex Pharmaceuticals, Inc.8
已完成
2 期
A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapyAdvanced or recurrent esophageal cancerJPRN-UMIN000019230niversity of Miyazaki Hospital25
招募中
2 期
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35
招募中
不适用
Paclitaxel in patients with GIST with low P-glycoprotein expression after failure of at least imatinib and sunitinib, and regorafenib.NeoplasmsKCT0003895Asan Medical Center40
已完成
2 期
Phase ll trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcomalocally advanced liposarcoma10072990NL-OMON45497European Organisation for Research in Treatment of Cancer (EORTC)9